Navigation Links
Cardiac Science Announces Inclusion in Russell 3000 Index
Date:6/30/2008

BOTHELL, Wash., June 30 /PRNewswire-FirstCall/ -- Cardiac Science Corporation (Nasdaq: CSCX), a global leader in advanced cardiac diagnosis, resuscitation, rehabilitation, and informatics products, announced today that it has been selected to join the Russell 3000(R) Index. The Company's addition to the Russell 3000 Index was made effective following the market close on Friday, June 27. Selection to the Russell 3000 index means Cardiac Science is automatically included in the Russell 2000(R) Index, which measures the performance of approximately 2,000 small-cap U.S. securities.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080306/AQTH510LOGO)

"We believe our inclusion in the Russell indexes will provide our company with greater visibility to a broader range of potential investors," said John Hinson, president and chief executive officer of Cardiac Science.

The Russell 3000 Index measures the performance of the largest 3,000 U.S. companies, and is constructed to provide a comprehensive, unbiased and stable barometer of the broad market. The Index is reconstituted annually. The Russell 2000 Index is a subset of the Russell 3000 Index.

About Cardiac Science

Cardiac Science develops, manufactures, and markets a family of advanced diagnostic and therapeutic cardiology devices and systems, including automated external defibrillators (AEDs), electrocardiograph devices (ECGs), cardiac stress systems and treadmills, Holter monitoring systems, hospital defibrillators, cardiac rehabilitation telemetry systems, and cardiology data management systems (informatics) that connect with hospital information (HIS), electronic medical record (EMR), and other information systems. The Company sells a variety of related products and consumables, and provides a portfolio of training, maintenance, and support services. Cardiac Science, the successor to the cardiac businesses that established the trusted Burdick(R), HeartCentrix(R), Powerheart(R), and Quinton(R) brands, is headquartered in Bothell, Washington. With customers in more than 100 countries worldwide, the company has operations in North America, Europe, and Asia. For information, call 425.402.2000 or visit http://www.cardiacscience.com.

CSCX-G

Company Contact: Investor Contact: Media Contact:

Mike Matysik Jenifer Kirtland or Christopher Gale

Cardiac Science Donald Takaya EVC Group, Inc.

Corporation EVC Group, Inc. (201) 646-5431

Sr. Vice President (415) 896-6820 (203) 570-4681

and CFO cgale@evcgroup.com

(425) 402-2009


'/>"/>
SOURCE Cardiac Science Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. CardiacAssist, Inc. Surpasses 1300 TandemHeart System Procedures
2. Cardiac Science Launches Anywhere Data Management for HIS and EMR Systems
3. Braemar Introduces the ER920W Wireless Cardiac Arrhythmia Monitor
4. Cardiac Science to Present at Needham Biotechnology & Medical Technology Conference
5. Perceptive Informatics Enhances Medical Imaging Capabilities for Assessment of Cardiac Function
6. Increased Drug Related Cardiac Toxicity Leads Gwathmey Preclinical Testing Services to Create Novel Cardionomics(TM) Services for Preclinical Cardiac Safety Screening of Drug Candidates
7. CorMatrix(R) Announces FDA 510(k) for Novel Biomaterial Implant for Intracardiac Repair
8. CryoLife Conducts Surgeons Cardiac Allograft Symposium
9. Cardiac Science Schedules First Quarter Earnings Release and Announces Conference Call
10. The Scripps Translational Science Institute Joins The MetaMiner Cardiac Consortium
11. eResearchTechnology, Inc. and nSpire Health, Inc. Form Alliance to Deliver Integrated Cardiac Safety and Pulmonary Clinical Trial Services
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... -- NetworkNewsWire Editorial Coverage  ... Cancer remains one of the ... care systems, in terms of costs and resources. However, as ... development of innovative and efficient therapies that demonstrate higher chances ... of cancer treatments, a growing number of patients receiving immuno-oncology ...
(Date:3/22/2017)... N.Y. , March 22, 2017 Regeneron Pharmaceuticals, ... the Regeneron Genetics Center (RGC), U.K. Biobank and GSK to ... the U.K. Biobank resource. The initiative will enable researchers to ... new medicines for a wide range of serious and life ... ...
(Date:3/22/2017)... 22, 2017 Oramed Pharmaceuticals Inc. (NASDAQ: ... www.oramed.com ), a clinical-stage pharmaceutical company ... systems, announced today that Dr. Miriam Kidron ... presentation titled, "Oral Insulin for Diabetes Treatment: Bypassing ... Institute,s Oligonucleotide and Peptide Therapeutics (OPT) Boston Conference in ...
(Date:3/22/2017)... 22, 2017   Boston Biomedical , an industry ... to target cancer stemness pathways, today announced its Board ... as Chief Executive Officer, effective April 24, 2017. ... Li , M.D., FACP, who has led Boston Biomedical ... his leadership, Boston Biomedical has grown from a "garage ...
Breaking Biology Technology:
(Date:2/28/2017)... LOS ANGELES , Feb. 28, 2017   ... identity verification software globally, announces significant enhancements to new ... in May 2016. New products include mobile and desktop ... and DocX TM - a real time manual ... Acuant,s core idScan® technology provides the fastest and most ...
(Date:2/26/2017)... -- Securus Technologies, a leading provider of civil and ... corrections and monitoring, announces the appointment of a ... often, too many offenders return to jail or ... to tackle this ongoing problem and improve the ... significant steps are underway, Securus continues to invest ...
(Date:2/21/2017)... , February 21, 2017 ... 70 Millionen US-Dollar wachsen. Nach einem Gespräch mit mehr als ... einige Hindernisse zu überwinden gilt, um diese Prognose zu ... ... anderem die Mobilisierung der finanziellen Mittel für die Biobank, ...
Breaking Biology News(10 mins):